









































Pa
ge

 
1



Pa
ge

 
44

American Journal of  Medical 
Science and Innovation (AJMSI) 

The Effects of  Hepatitis Therapy and Virus Resistance on Pregnant Women: A 
Comprehensive Analysis

Ilham T. Qattan1*

Volume 3 Issue 2, Year 2024
ISSN: 2836-8509 (Online)

DOI: https://doi.org/10.54536/ajmsi.v3i2.2991
https://journals.e-palli.com/home/index.php/ajmsi

Article Information ABSTRACT

Received: June 27, 2024
Accepted: July 31, 2024
Published: August 03, 2024

This study aims to provide a comprehensive analysis of  the effects of  hepatitis therapy and 
virus resistance on pregnant women. Hepatitis, a liver condition that is often regarded as a 
viral infection, poses considerable risks during pregnancy for both the mother’s and baby’s 
health. In viral hepatitis (like hepatitis B or C), the risk of  negative outcomes and liver 
damage increases dramatically for expecting women as well as for fetus health. In addition to 
antiviral therapy (considering the drug safety, efficacy, and resistance issue), vaccination and 
preventive measures are important components of  the treatment process. The purpose of  
this manuscript is to critically examine the literature that is currently accessible to illuminate 
the most crucial aspects or elements and provide useful input into treatment strategy 
optimization for pregnant women afflicted with hepatitis. While remarkable advancements 
have been made, screening and diagnostic services demand improvements and illustrate the 
need for efficient measures to abridge the impact of  this viral hepatitis on pregnant women 
and their newborn babies. 

Keywords
Hepatitis Therapy, Pregnancy, 
Viral Resistance, Maternal-
Fetal-Health, Viral Load

1 Taibah University, Janadah Bin Umayyah Road, Tayba, Madinah 42353, Saudi Arabia
* Corresponding author’s e-mail: it.qattan54@outlook.com

INTRODUCTION
A broad range of  conditions, including heavy alcohol 
consumption, autoimmune diseases, medications, and 
toxins, can induce inflammation of  the liver, which is 
known as hepatitis. On the other hand, viral hepatitis, 
which results from a viral infection, is the most common 
cause of  hepatitis. Hepatitis is acute when it lasts less than 
six months and chronic when it persists longer. It may 
occur with limited or no symptoms but often leads to 
other diseases, such as anorexia (poor appetite), jaundice, 
and malaise (Aljumah et al., 2019). The most recent WHO 
global hepatitis report states that liver problems from all 
types of  hepatitis viruses result in 1.34 million deaths 
annually (com, 2023). There are five known hepatitis 
viruses, A through E. The three most prevalent viral 
hepatitis kinds are hepatitis A, hepatitis B, and hepatitis C. 
Hepatitis D and E are the other forms of  viral hepatitis 
that are less common (Mehta & Reddivari, 2022). Whereas 
Hepatitis D is considered a subgroup of  hepatitis B due 
to its need for concurrent infection with hepatitis B. 
Pregnancy can impact all aspects of  these viral agents due 
to distinct immunologic and physiological changes during 
and after gestation (Shata et al., 2022).
Hepatitis, a viral illness, has become a leading cause of  
fetal deaths during pregnancy and has an association 
with high-risk complications for the mother (Chilaka & 
Konje, 2021; Jaffe & Brown Jr, 2017; Seto et al., 2020). 
Viral hepatitis with the origin from pregnancy is a very 
difficult problem that would have better be dealt with 
since it may seriously harm the mother’s and fetus` health. 
Acute progression is present in hepatitis A and hepatitis 
E, while the mortality risk and the high fetal deaths are 
high in hepatitis E. Further, hepatitis B and C have been 
tightly linked to being chronic, and yet women transmit 

the viruses to their unborn children (MTCT) (Terrault et 
al., 2021). 
Pregnancy tends to worsen pre-existing viral disease 
conditions due to the numerous pregnancy-induced 
immigration, immunity-related, and gene-oriented 
changes. Just the same, hepatitis E causes fatality in 
about 26% of  suspected cases among pregnant women  
(Bergløv et al., 2019). 
Pregnancy can contribute to physiologic parameter 
alterations, giving physicians different treatment 
indications than the general population. Consequently, 
the picture of  the safety and efficacy of  drugs and 
vaccinations during pregnancy is constantly developing. 
It is still critically important to implement a preventive 
mechanism that cuts the levels of  this transmission. 
Furthermore, to diagnose hepatitis different methods 
are being used namely, ICT, ELISA, CMIA and PCR 
(Rahaman et al., 2023).
This paper aims to facilitate a comprehensive examination 
of  how pregnant women are affected by anti-hepatitis 
medicine and genetic resistance to the virus. Liver-
damaging hepatitis, a virus that creates hazards for the 
mother as well as for the unborn child during pregnancy, 
is what poses these risks. Current antiviral therapy is an 
integral component of  curing HCV, yet its downside 
problems, including poor efficiency, toxicity, and 
treatment resistance, must be agreed upon. This research 
aims to further clarify these crucial points by critically 
reviewing the literature and proposing recommendations 
to enhance the treatment of  pregnant hepatitis patients.

LITERATURE REVIEW
Pregnant Women with Hepatitis
Viral hepatitis out of  pregnancy has always been in 



Pa
ge

 
45

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 3(2) 44-51, 2024

debate. This condition caused a major mortality rate 
during childbearing. The opinions of  researchers over 
the impacts of  viral hepatitis among pregnant women 
on both the mother and fetus also differ. While some 
researchers considered it wrong that non-fatal viral 
hepatitis did not affect the course of  pregnancy or would 
not bring harm to the baby, others found that acute viral 
hepatitis presented a substantial danger to both mother 
and fetus(Asafo-Agyei & Samant, 2020). Moreover, 
the liver damage caused by hepatitis in every trimester 
depends on the virus type and is also associated with the 
intensity of  it.
HAV, an RNA virus, is highly endemic in the Middle 
East, North Africa, Sub-Saharan Africa, South and 
Central Asia, and Latin America. Its infections are 
mostly self-limited and rarely cause life-threatening 
consequences. The death rate ranges from 0.3% to 
0.6%, with an estimated 1.5 million new cases reported 
annually. Efficient and secure vaccination prevents HAV 
infection (Chaudhry et al., 2015).
Hepatitis B is an infectious virus that causes liver 
infections in primates. It is transmitted through parenteral 
blood exposure, sexual contact, or vertical transmission 
from mother to child during or after delivery. The 
natural history of  this disease is complex. Acute 
infection can result in jaundice, pain, and liver failure. 
The non-resolving infection will lead to scarring of  the 
liver, which will eventually lead to cancer (Shata et al., 
2022). Infection severity will predict risk. Furthermore, 
research demonstrated that pregnant women with 
HBV infection tend to get preeclampsia and gestational 
diabetes in addition to hepatitis B infection during 
pregnancy; therefore, the extent of  the problem should 
be investigated (Afraie et al., 2023).
Pregnancy-related HCV-positive cases can have a huge 
impact on both the mother having an increased viral 
load and low levels of  liver transaminases. Trending 
liver function when pregnant is not advised. Intrahepatic 
cholestasis, gestational hyperglycemia, and worsening 
fetal outcomes are further related disorders. However, it is 
recommended that women with HCV infection undergo 
a growth scan during the third trimester (Dotters-Katz 
et al., 2021). Moreover, newborns delivered by mothers 
who test positive for HCV are more likely to have low 
birthweights and need to be admitted to a neonatal 
intensive care unit or on assisted ventilation. The 
intravenous drug usage of  mothers does not appear to 
have an impact on these results (Aebi-Popp et al., 2016).
Moreover, In the West, 40% of  episodes of  jaundice in 
pregnant women are caused by viral hepatitis A through 
E. The majority of  cases are anicteric and subclinical, 
with symptoms such as jaundice, headache, nausea, and 
vomiting. Only a small proportion of  hepatitis C cases 
exhibit full recovery, compared to all cases of  hepatitis 
A and B, which show full recovery (García-Romero et 
al., 2019). Furthermore, Replication of  the hepatitis D 
virus (HDV) requires HBV infection. It coats itself  with 
more HBsAg protein and enters hepatocytes. There are 

few pregnancies and HDV transmissions from mother to 
child (Sellier et al., 2018).
According to a study, there have been reports of  vertical 
transmission of  HAV and HEV from mother to child 
(Terrault et al., 2021). Hepatitis A and E have severe 
complications in pregnant women, which can be caused by 
drinking contaminated water. Additionally, the hepatitis A 
virus can lead to early labour, whereas HEV infection in 
the second or third trimester entails significant morbidity 
and death concerns (com, 2023). 
A study evidenced that pregnant women had an 11.6% 
prevalence of  the hepatitis E virus (HEV), with 11.4% 
testing positive for the anti-HEV IgG antibody, 0.1% 
for the anti-HEV IgM antibody, and 0.1% for both 
antibodies. HEV-IgG antibody-positive pregnant women 
are more likely to experience bad pregnancy outcomes, 
liver damage, and poor maternal and fetal outcomes. 
These unfavorable pregnancy outcomes are worsened by 
parity, age, and gravidity (Qian et al., 2023). Furthermore, 
studies have shown that the replication of  the hepatitis E 
virus in the placenta is associated with maternal and fetal 
mortality with acute liver failure. The study also found 
that in HEV patients, receptors of  estrogen ESR1α 
and ESR2β and estrogen itself  have been identified as 
possible biomarkers predicting worse maternal and fetal 
health (Horvatits et al., 2019).

Diagnosis and Monitoring
People diagnosed with hepatitis should emergently 
seek monitoring. Diagnosing and monitoring of  
hepatitis include imaging and a number of  blood tests. 
Furthermore, in pregnant women, the key blood tests 
used to diagnose and monitor hepatitis include Hepatitis 
antibody serology tests, liver function tests, and viral 
load assessment (Asafo-Agyei & Samant, 2020). A study 
regarding HBV infection stated that the antibodies 
HBeAg, anti-HBs, HBsAg, anti-HBe, and anti-HBc IgM 
and IgG are among the serological indicators of  HBV 
infection. These markers aid in the diagnosis of  HBV 
infection, comprehension of  the progression of  chronic 
hepatitis B (CHB), evaluation of  the clinical stages, and 
tracking of  antiviral treatment. The main marker, HBsAg, 
is at higher levels in CHB patients who test positive 
for HBeAg. Long-term immunity is provided by anti-
HBs, which coexists with anti-HBc IgG. During acute 
infection, anti-HBc IgM and IgG emerge after HBsAg, 
and HBV DNA assays take the role of  earlier indicators 
(Song, 2016). 
Secondly, most commonly, abnormal liver function 
results in the third trimester (Mishra et al., 2016). In order 
to evaluate liver function and identify any abnormalities, 
liver function tests, or LFTs, are essential during 
pregnancy. They take albumin, bilirubin, and enzyme 
readings. Timely care and the reduction of  problems 
depend on the accurate interpretation of  LFT results. 
In order to protect pregnant women and their unborn 
children, these tests assist medical professionals in 
keeping an eye on liver health, spotting anomalies, and 



Pa
ge

 
46

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 3(2) 44-51, 2024

starting interventions. Furthermore, the interpretation of  
abnormal liver function tests (ALFTs), which are essential 
for the diagnosis of  liver disease, can be difficult during 
pregnancy because of  hemodilution and physiological 
changes. Pregnant women’s transaminases, especially ALT 
(Alanine Aminotransferase) and GGT (Gamma Glutamyl 
Transferase), are 20% lower than laboratory reference 
levels, while their alkaline phosphatase increases because 
of  the placenta. (Dajti et al., 2023).
HCV+ mothers don’t need to monitor transaminases 
during pregnancy; measuring liver enzymes at the start 
of  pregnancy is adequate. A single pregnancy-related 
qualitative PCR test is recommended, but any liver disease 
staging should wait until after delivery. Furthermore, 
since there is currently no anti-HCV medication that can 
be given to expectant mothers to stop viral replication, a 
high maternal viral load is a significant but avoidable risk 
factor (Tovo et al., 2016)
At Ghent University Hospital, a study assessed three 
PCR assays and six serological assays to identify HEV 
in individuals who may have been infected. Using 
commercial ELISA and PCR assays, including in-house 
and commercial testing, they looked for HEV RNA and 
antibodies (IgM and IgG) specific to the virus. Across 
all ELISA assays, the frequency of  HEV antibodies 
ranged from 5.7% to 14.3% for IgM and 15.7% to 20.0% 
for IgG. In clinical samples, most PCR findings were 
consistent; however, there were notable differences in 10 
out of  16 external quality control samples (Cattoir et al., 
2017). Another study concluded that the anti-HEV Ag-
specific ELISA is less sensitive than HEV RNA real-time 
PCR. Yet, it is a valuable tool for distinguishing chronic 
from acute infection (Behrendt et al., 2016).
Furthermore, new research develops a method for 
identifying HBV perinatal transmission utilizing fast DNA 
extraction and recombinase polymerase amplification. 
The assay achieved 98.6% sensitivity and 88.2% specificity, 
with room for improvement in non-viremic patients. The 
study proposes that this approach be utilized in point-of-
care testing to avoid HBV transmission. However, more 
validation on a larger cohort of  HBV-positive plasma 
samples from pregnant women is required before in-field 
adoption (Mayran et al., 2022).

Hepatitis Therapy and Medications in Pregnant 
Women
Most of  the research has developed on treatment and 
therapy for hepatitis B and hepatitis C. Chronic Hepatitis 
B (CHB) has turned out to be a prominent health problem 
on a global scale, and the management of  pregnant women 
with this disease is a necessity. Pregnant women will be 
running tests like hepatitis B surface antigen (HBsAg) 
and other tests. The management primarily focuses on 
the HBV infection stage rather than pregnancy since 
the latter state is hardly indicated. Antiviral treatment 

is intended mainly for indicated CHB patients and 
also for anti-vertical transmission purposes. Tenofovir 
should be taken during pregnancy. Use a combination 
of  hepatitis B immunoglobulin and vaccination for all 
infants whose mothers are infected with CHB, insisting 
on no breastfeeding contraindications (Belopolskaya et 
al., 2021).
HCV is strongly associated with premature birth and 
cholestasis. Till now, there is no vaccine for hepatitis C, so 
the main focus is on the treatment. For the treatment of  
children with HCV transmitted through the mother, anti-
HCV antibodies that pregnant women possess can be 
transmitted through the placenta to the fetus. The period 
of  the baby’s serum can be detected in the same maternal 
antibodies for up to 13 months after birth. Diagnosed 
with antibody titer rise in the newborn serum does not 
mean they’re infected (Ragusa et al., 2020). 
A study in Switzerland found that many pregnant women 
with HCV are unaware of  their condition, and regular 
screening is not done. The Federal Office of  Public Health 
and the Swiss Society of  Obstetrics and Gynecology 
recommend HCV testing for high-risk women, including 
those who have used intravenous drugs, had HCV 
infection, received a solid organ transplant before 1992, 
received blood transfusions, or used clotting factor 
concentrate before 1987. Untrustworthy self-reporting 
of  drug use during pregnancy is a significant obstacle to 
diagnosis (Aebi-Popp et al., 2016).

Study Design and Methodology
Search Strategy
This literature review employed a systematic search 
strategy to identify relevant studies published in peer-
reviewed journals. Electronic databases, including 
PubMed Google Scholar, PubMed, Science Direct, and 
Springer Link, were searched using predefined search 
terms related to HBV screening in pregnant women using 
keywords: hepatitis A, hepatitis B, hepatitis C, Hepatitis 
D, hepatitis E, pregnancy, viral resistance, treatment, 
hepatitis therapy, and diagnosis of  hepatitis.

Inclusion and Exclusion Criteria
Articles were limited to those published in English from 
2015 to 2024. This review includes only hepatitis-related 
articles, including therapeutic approaches to hepatitis in 
pregnant women. It excludes all those studies which do not 
include hepatitis in pregnant women. Studies published in 
journals where publishers do not offer a peer-reviewing 
policy were excluded, and only studies available in full-
text format for the public view were included.

RESULTS
The results of  selected studies are presented in a table 
representing the author, years, published journal, title of  
the study objectives, and results.



Pa
ge

 
47

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 3(2) 44-51, 2024

Table 1: Shows the objectives and results of  the studies discussed in the review
S. 
No 

Author Journal Title Objective Results

1.
(Q

ia
n 

et 
al.

, 2
02

3)

Jo
ur

na
l o

f 
C

lin
ic

al
 V

iro
lo

gy

Prevalence Of  
Hepatitis E 
Virus And Its 
Association 
With Adverse 
Pregnancy 
Outcomes 
In Pregnant 
Women In 
China

To investigate the 
prevalence of  (HEV) 
infection among 
pregnant women and to 
assess the association 
between HEV infection, 
specifically the presence 
of  anti-HEV IgG 
antibodies, and adverse 
pregnancy outcomes.

The existence of  anti-HEV IgG 
antibodies has been linked to an 
increased risk of  bad pregnancy 
outcomes, such as liver damage 
and poor mother and fetal health. 
Furthermore, the study found parity, 
age, and gravidity as factors that 
exacerbated the negative pregnancy 
outcomes linked with HEV infections.

2.

(S
on

g,
 2

01
6)

A
nn

al
s o

f 
Tr

an
sla

tio
na

l M
ed

ic
in

e

Diagnosis Of  
Hepatitis B

The study aimed 
to investigate the 
serological indicators 
of  hepatitis B virus 
(HBV) infection and 
their involvement in the 
diagnosis, progression 
monitoring, and therapy 
evaluation of  chronic 
hepatitis B.

The study found various serological 
indications of  hepatitis B virus 
infection, including HBeAg, anti-HBs, 
HBsAg, anti-HBe, and anti-HBc IgM 
and IgG. The key marker, HBsAg, 
is present at high levels in chronic 
hepatitis B patients. Anti-HBs provide 
long-term protection, whereas anti-
HBc IgM and IgG antibodies appear 
during acute infection. These findings 
advance our understanding of  HBV 
infection and influence management 
options.

3.

(C
at

to
ir 

et 
al.

, 2
01

7)

A
rc

hi
ve

s O
f 

V
iro

lo
gy

Hepatitis E 
Virus Serology 
and PCR: 
Does The 
Methodology 
Matter?

The study aimed 
to compare the 
performance of  six 
serological assays and 
three PCR assays in 
detecting Hepatitis E 
virus (HEV) genotype 
3 in patients with 
clinically suspected 
HEV infection at Ghent 
University Hospital.

The study discovered variable 
prevalence rates of  HEV antibodies, 
with IgM and IgG antibodies ranging 
from 5.7% to 20.0%. HEV RNA 
was detected using a commercial test 
and two optimized in-house real-
time RT-PCR techniques. Most PCR 
findings were consistent. However, 10 
of  16 external quality control samples 
exhibited significant differences in PCR 
assays. This emphasizes the importance 
of  carefully interpreting serological and 
molecular HEV infection test data.

4.

(M
ay

ra
n 

et 
al.

, 2
02

2)

D
ia

gn
os

tic
s

Rapid 
Diagnostic Test 
For Hepatitis 
B Virus Viral 
Load Based On 
Recombinase 
Polymerase 
Amplification 
Combined With 
A Lateral Flow 
Read-Out

This research aimed 
to develop a simple 
molecular method for 
detecting highly viremic 
pregnant women with 
Hepatitis B virus (HBV) 
infection, which is 
an important step in 
preventing perinatal 
transmission.

A study proposed a method for 
identifying HBV perinatal transmission 
utilizing fast DNA extraction and an 
isothermal recombinase polymerase 
amplification (RPA) technology. 
The approach was tested on plasma 
samples with different virus loads and 
genotypes. The assay had a sensitivity 
of  98.6%, indicating efficacy in 
detecting highly viremic individuals, 
and a specificity of  88.2%, indicating 
room for improvement in recognizing 
non-very viremic cases. The assay’s 
high overall performance suggests 
its potential for use in point-of-care 
testing.



Pa
ge

 
48

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 3(2) 44-51, 2024

5.

(A
eb

i-P
op

p 
et 

al.
, 2

01
6)

Jo
ur

na
l o

f 
V

iru
s E

ra
di

ca
tio

n

Vertical 
Transmission 
of  Hepatitis 
C: Towards 
Universal 
Antenatal 
Screening in 
The Era of  New 
Direct Acting 
Antivirals 
(Daas)? Short 
Review And 
Analysis Of  
The Situation In 
Switzerland

The study aimed to 
determine the frequency 
of  undetected Hepatitis 
C virus (HCV) infection 
among pregnant women 
in Switzerland, taking 
into account the lack of  
routine screening and 
the difficulties associated 
with self-reporting 
behaviors at high risk.

Unreliable self-reporting of  drug 
use during pregnancy appeared as 
a substantial hindrance to proper 
diagnosis. These findings highlight 
the significance of  establishing more 
effective screening procedures and 
resolving self-reporting problems to 
improve the detection and management 
of  HCV infection among pregnant 
women in Switzerland.

6.

(B
eh

re
nd

t e
t a

l., 
20

16
)

T
he

 Jo
ur

na
l o

f 
in

fe
ct

io
us

 d
ise

as
es

Hepatitis E 
virus (HEV) 
ORF2 
antigen levels 
differentiate 
between acute 
and chronic 
HEV infection.

The study aimed to 
evaluate the effectiveness 
of  an ELISA-specific 
enzyme-linked 
immunosorbent assay in 
detecting HEV genotype 
3 infections, comparing 
its sensitivity with real-
time PCR and assessing 
its ability to differentiate 
between acute and 
chronic infections.

Compared to real-time PCR, the 
anti-HEV Ag-ELISA showed lower 
sensitivity in detecting HEV infection 
but higher levels in chronically infected 
individuals. It also demonstrated 
high sensitivity and specificity in 
distinguishing acute and chronic HEV 
infections. Despite its less sensitive 
nature, it remains a valuable tool for 
HEV infection diagnosis.

7.

(B
el

op
ol

sk
ay

a 
et 

al.
, 2

02
1)

W
or

ld
 Jo

ur
na

l o
f 

G
as

tro
en

te
ro

lo
gy

Chronic 
hepatitis B 
in pregnant 
women: Current 
trends and 
approaches

The primary objective in 
treating pregnant women 
with Hepatitis B virus 
(HBV) infection is to 
prevent the virus from 
passing from mother 
to child. This includes 
carrying out essential 
examinations, such as 
the hepatitis B surface 
antigen (HBsAg), to 
determine the mother’s 
infection status and 
applying the related 
management practices.

The management of  infected pregnant 
women should involve carrying out 
relevant tests like HBsAg to determine 
the mother’s status. Management 
should focus on the stage of  HBV 
infection rather than pregnancy itself, 
as pregnancy only marginally affects 
HBV progression. Antiviral treatment 
that contains tenofovir, for instance, 
should be prescribed for pregnant 
women with indicated chronic 
HBV infection to reduce the risk of  
vertical transmission. A combination 
of  hepatitis B immunoglobulin and 
vaccination for every infant born 
to a chronic HBV carrier with the 
crucial point of  close adherence to 
recommended breastfeeding practices 
to make transmission less likely.

DISCUSSION
This literature review concentrates on Hepatitis A, B, 
C, D, and E influences during pregnancy. It provides 
an extensive overview of  the risks the mother and fetus 
share. It highlights the need for designing newer regimens 
for screening, diagnosing, and treating cases of  hepatitis 
in women during pregnancy. 
The evidence shows that viral hepatitis is one of  the main 
causes of  fetal death during pregnancy, and the paper 
highlights the high-risk problems viral hepatitis poses to 

pregnant women. The paper looks at the different forms 
of  viral hepatitis that appear throughout pregnancy, 
which include an acute disease progression in hepatitis A 
and E, a chronic disease form in hepatitis B and C, and 
the yet-to-be-described risks of  preeclampsia, gestational 
diabetes, and intrahepatic cholestasis.
The review also briefly describes the difficulties in 
diagnosing and controlling viral hepatitis in pregnant 
women, the interpretation of  liver function tests, and 
the impact of  physiological changes during pregnancy 



Pa
ge

 
49

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 3(2) 44-51, 2024

on diagnostic markers. Diagnosing and managing viral 
hepatitis in pregnancy has significant challenges as 
evidenced by many studies. Some physiological changes 
that occur during pregnancy include changes that involve 
liver function and hormones, and therefore, diagnostic 
test results may be affected. When it comes to the 
assessment of  liver health, LFTs are essential though 
they may be affected by pregnancy’s normal physiological 
changes, thus presenting challenges for the distinction of  
pathological changes from normal fluctuations.
Besides, the fact that viral hepatitis interacts with the 
human body constantly, with periodically escalating and 
decreasing viral replication rates and immune responses, 
complicates matters even further. Particularly, pregnancy 
could change clinical characteristics in a patient, as well 
as the progression of  the disease; therefore, diagnosis 
becomes problematic. Managing viral hepatitis in this 
population is also challenging due to the possible 
teratogenic effects of  the antiviral agents and the potential 
consequences that coordination between the health of  
the mother and the fetus may have. 
The issues that arise should be solved on the basis of  
a multidisciplinary approach through the cooperation 
between obstetricians, hepatologists, and specialists 
in infectious diseases; it will be possible to assess the 
management and prevent possible negative outcomes for 
both the mother and the fetus. The paper covers another 
aspect of  the effects of  hepatitis on fetal health, such as 
preterm delivery and the risk of  newborn complications.
Additionally, for the treatment of  HEV, Ribavirin and 
interferon alpha are effective, but in pregnancy, the use of  
these agents is inhibited and is not suggested. However, 
ribavirin can be recommended for pregnant women 
infected with HEV in the last trimester due to its less 
teratogenic effects (Aslan & Balaban, 2020).
Furthermore, the study by Anisweka et al. (2019) indicates 
the role of  antiviral treatment in the course of  hepatitis 
during the period of  pregnancy, concerning both 
acute subtypes B and C. It stresses the involvement of  
tenofovir in pregnancy to minimize the risk of  vertical 
transmission and birth immunoglobulin and vaccination 
in not transmitting hepatitis B to newborns. Besides 
this, the review is about the progress in diagnosing 
viral hepatitis, achieved by rapid DNA extraction and 
recombinase polymerase amplification. These appear 
useful in determining highly viremic and hepatitis B 
pregnant ladies.
Furthermore, the report by the researcher shows the 
importance of  effective screening policies aimed at 
discovering HCV infection among pregnant women. It 
is worth noting that many infected individuals are only 
detected by diagnostic examinations, which signifies the 
importance of  screening programs. Healthcare providers, 
including gynecologists, obstetricians, and other 
clinicians, are having a significant impact on the early 
detection and diagnosis of  HCV in pregnant women. The 
research equally indicates that the forward increase or the 
dominance of  intravenous drug use among pregnant 

women calls for special considerations regarding maternal 
and fetal health outcomes, further justifying the need for 
tailor-made solutions that address drug abuse during 
pregnancy (Aniszewska et al., 2019).
Moreover, it is of  vital importance for the medical 
care provider to consider viral hepatitis among high-
risk pregnancy women to avoid maternal and fetal 
complications that are linked with mother-to-child 
transmission. Holistic care of  the mother requiring 
obstetrics, maternal-fetal medicine, hepatology, and 
neonatology is desired to ensure the best chances for 
both mother and child. It is recommended that pregnant 
women be tested for HBV and HCV as part of  routine 
screening. Tenofovir Disoproxil Fumarate, Lopinavir, and 
Ritonavir with Antiviral Therapy may be required, while 
Lamivudine may be considered an option. Given the 
knowledge regarding the safety and efficacy of  Direct-
Acting Antivirals in HCV infection during pregnancy and 
Food and Drug Administration approval, the outcomes 
of  clinical practices should be enhanced and improved 
(Sanghi & Lindenmeyer, 2021).
Alhussain et al. in his research studied about perinatal care 
and concluded that counselling on coping and stressor 
adaptation mechanisms should be provided to everyone 
during public health emergencies (Alhussain et al., 2023)
In conclusion, it is distinct that the diagnosis and 
management of  viral hepatitis during pregnancy remain 
complicated due to the changes in physiological status. 
It is challenging to pinpoint what may be considered as 
a range of  normal variations and what requires a special 
consideration of  pathological changes affecting liver 
function tests, and their impact on the diagnostic markers. 
Thirdly, due to the high viral loads as well as the variability 
of  the immune responses, diagnosis of  viral hepatitis is 
not a very easy process.

CONCLUSION
To summarize, the hepatitis care of  pregnant women is 
intricate, involving multiple obstacles and complexities, 
from diagnostic precision to treatment decisions. Though 
the literature review points out the already existing 
measures like diagnosis, monitoring, and therapy in 
different ways, shortcomings and unresolved issues still 
require further studies.

Limitations and Future Implications
The review on hepatitis management during pregnancy 
gives us a great range of  information about therapeutic 
approaches, diagnosis, and monitoring. Nevertheless, 
a few barriers and topics have not been extensively 
explored. It is basically about therapeutic modalities and 
diagnostic methods, and it doesn’t touch upon aspects 
such as epidemiology and social impacts. One aspect that 
could limit data transferability from one region to another 
is the data regional variation. Publish bias is another issue, 
as only the studies published in English between 2015 and 
2024 have been included in this review. Scientific research 
in this domain is challenging due to methodological 



Pa
ge

 
50

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 3(2) 44-51, 2024

discrepancies across studies, making it hard to establish 
a solid, unified conclusion. Thus, longitudinal follow-
up of  fetal and mother outcomes is lacking. Still, more 
studies on genes that affect offense or susceptibility and 
treatment are required. Interventional studies that assess 
the effectiveness and safety of  treatment modalities are, 
too, in short supply. Overcoming these constraints will 
provide us with a better insight into managing hepatic 
conditions in pregnancy and will lead to better outcomes 
for mothers and babies.

REFERENCES
Aebi-Popp, K., Duppenthaler, A., Rauch, A., De Gottardi, 

A., & Kahlert, C. (2016). Vertical transmission of  
hepatitis C: towards universal antenatal screening in 
the era of  new direct acting antivirals (DAAs)? Short 
review and analysis of  the situation in Switzerland. 
Journal of  virus eradication, 2(1), 52-54. 

Afraie, M., Moradi, G., Zamani, K., Azami, M., & Moradi, 
Y. (2023). The effect of  hepatitis B virus on the risk of  
pregnancy outcomes: a systematic review and meta-
analysis of  cohort studies. Virology Journal, 20(1), 213. 

Alhussain, K., Alhussain, F., Mirasol, J., & Alotaibi, N. 
(2023). Influence of  Covid-19 Pandemic on Prenatal 
Care Utilization and Birth outcome-Qualitative 
Systematic Review Protocol. American Journal of  
Medical Science and Innovation, 2(2), 206-215. 

Aljumah, A. A., Al-Ashgar, H., Fallatah, H., & 
Albenmousa, A. (2019). Acute onset autoimmune 
hepatitis: Clinical presentation and treatment 
outcomes. Annals of  Hepatology, 18(3), 439-444. 

Aniszewska, M., Pokorska-Śpiewak, M., Kowalik-
Mikołajewska, B., Pluta, M., & Marczyńska, M. 
(2019). Hepatitis C infection among pregnant women 
in central Poland: Significance of  epidemiological 
anamnesis and impact of  screening tests to detect 
infection. Advances in clinical and experimental medicine, 
28(3), 313-318. 

Asafo-Agyei, K. O., & Samant, H. (2020). Pregnancy and 
viral hepatitis. 

Aslan, A. T., & Balaban, H. Y. (2020). Hepatitis E virus: 
Epidemiology, diagnosis, clinical manifestations, and 
treatment. World journal of  gastroenterology, 26(37), 5543. 

Behrendt, P., Bremer, B., Todt, D., Brown, R. J., Heim, 
A., Manns, M. P., Steinmann, E., & Wedemeyer, H. 
(2016). Hepatitis E virus (HEV) ORF2 antigen levels 
differentiate between acute and chronic HEV infection. 
The Journal of  infectious diseases, 214(3), 361-368. 

Belopolskaya, M., Avrutin, V., Kalinina, O., Dmitriev, A., 
& Gusev, D. (2021). Chronic hepatitis B in pregnant 
women: Current trends and approaches. World journal 
of  gastroenterology, 27(23), 3279. 

Bergløv, A., Hallager, S., & Weis, N. (2019). Hepatitis E 
during pregnancy: maternal and foetal case‐fatality 
rates and adverse outcomes—a systematic review. 
Journal of  Viral Hepatitis, 26(11), 1240-1248. 

Cattoir, L., Van Hoecke, F., Van Maerken, T., Nys, E., 
Ryckaert, I., De Boulle, M., Geerts, A., Verhelst, 

X., Colle, I., & Hutse, V. (2017). Hepatitis E virus 
serology and PCR: does the methodology matter? 
Archives of  virology, 162, 2625-2632. 

Chaudhry, S. A., Verma, N., & Koren, G. (2015). Hepatitis 
E infection during pregnancy. Canadian Family 
Physician, 61(7), 607-608. 

Chilaka, V. N., & Konje, J. C. (2021). Viral Hepatitis in 
pregnancy. European Journal of  Obstetrics & Gynecology 
and Reproductive Biology, 256, 287-296. 

com, B. M. B. b. (2023). Safeguarding mothers and 
newborns: the urgent need to address hepatitis during 
pregnancy. BMC medicine, 21(1), 284. 

Dajti, E., Bruni, A., Barbara, G., & Azzaroli, F. (2023). 
Diagnostic Approach to Elevated Liver Function 
Tests during Pregnancy: A Pragmatic Narrative 
Review. Journal of  Personalized Medicine, 13(9), 1388. 

Dotters-Katz, S. K., Kuller, J. A., Hughes, B. L., & 
Medicine, S. f. M.-F. (2021). Society for maternal-
fetal medicine consult series# 56: Hepatitis C in 
pregnancy—updated guidelines: Replaces Consult 
Number 43, November 2017. American Journal of  
Obstetrics and Gynecology, 225(3), B8-B18. 

García-Romero, C. S., Guzman, C., Cervantes, A., & 
Cerbón, M. (2019). Liver disease in pregnancy: 
Medical aspects and their implications for mother and 
child. Annals of  Hepatology, 18(4), 553-562. 

Horvatits, T., Schulze zur Wiesch, J., Lütgehetmann, M., 
Lohse, A. W., & Pischke, S. (2019). The clinical perspective 
on hepatitis E. Viruses, 11(7), 617. 

Jaffe, A., & Brown Jr, R. S. (2017). A review of  antiviral 
use for the treatment of  chronic hepatitis B virus 
infection in pregnant women. Gastroenterology & 
Hepatology, 13(3), 154. 

Mayran, C., Foulongne, V., Van de Perre, P., Fournier-
Wirth, C., Molès, J.-P., & Cantaloube, J.-F. (2022). 
Rapid diagnostic test for hepatitis B virus viral load 
based on recombinase polymerase amplification 
combined with a lateral flow read-out. Diagnostics, 
12(3), 621. 

Mehta, P., & Reddivari, A. K. R. (2022). Hepatitis. In 
StatPearls [Internet]. StatPearls Publishing. 

Mishra, N., Mishra, V., & Thakur, P. (2016). Study of  
abnormal liver function test during pregnancy in a 
tertiary care hospital in Chhattisgarh. The Journal of  
Obstetrics and Gynecology of  India, 66, 129-135. 

Qian, Z., Li, T., Zhang, Y., Chen, S., Zhang, H., k Mickael, 
H., Xiu, D., Xia, Y., Cong, C., & Xu, L. (2023). 
Prevalence of  hepatitis E virus and its association 
with adverse pregnancy outcomes in pregnant women 
in China. Journal of  Clinical Virology, 158, 105353. 

Ragusa, R., Corsaro, L. S., Frazzetto, E., Bertino, E., 
Bellia, M. A., & Bertino, G. (2020). Hepatitis C 
virus infection in children and pregnant women: an 
updated review of  the literature on screening and 
treatments. American Journal of  Perinatology Reports, 
10(01), e121-e127. 

Rahaman, S., Islam, S., Sakib, K. R. I., Ferdous, K., Islam, 
M. N. I., Hossen, M. A.-A., & Rahman, M. A. (2023). 



Pa
ge

 
51

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 3(2) 44-51, 2024

Comparison of  ELISA & ICT Methods Determining 
Hepatitis B Surface in Suspected Patient Attending 
at Bangladesh Institute of  Health Science (BIHS) 
General Hospital, Dhaka. American Journal of  Medical 
Science and Innovation, 2(2), 31-35. 

Sanghi, V., & Lindenmeyer, C. C. (2021). viral Hepatitis 
in Pregnancy: an Update on screening, Diagnosis, and 
Management. Clinical Liver Disease, 18(1), 7-13. 

Sellier, P. O., Maylin, S., Brichler, S., Berçot, B., Lopes, A., 
Chopin, D., Pogliaghi, M., Munier, A. L., Delcey, V., & 
Simoneau, G. (2018). Hepatitis B virus‐hepatitis D virus 
mother‐to‐child co‐transmission: a retrospective study 
in a developed country. Liver International, 38(4), 611-618. 

Seto, M. T.-y., Cheung, K. W., & Hung, I. F. (2020). 
Management of  viral hepatitis A, C, D and E in 

pregnancy. Best Practice & Research Clinical Obstetrics & 
Gynaecology, 68, 44-53. 

Shata, M. T. M., Hetta, H. F., Sharma, Y., & Sherman, K. 
E. (2022). Viral hepatitis in pregnancy. Journal of  Viral 
Hepatitis, 29(10), 844-861. 

Song, J. E. (2016). Diagnosis of  hepatitis B. Annals of  
translational medicine, 4(18). 

Terrault, N. A., Levy, M. T., Cheung, K. W., & Jourdain, 
G. (2021). Viral hepatitis and pregnancy. Nature reviews 
Gastroenterology & hepatology, 18(2), 117-130. 

Tovo, P.-A., Calitri, C., Scolfaro, C., Gabiano, C., & 
Garazzino, S. (2016). Vertically acquired hepatitis 
C virus infection: Correlates of  transmission and 
disease progression. World journal of  gastroenterology, 
22(4), 1382. 


